an analysis of tp53 mutation in aml and hr-mds
Published 2 years ago • 476 plays • Length 5:16Download video MP4
Download video MP3
Similar videos
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
3:22
is tp53-mutated high-risk mds the same disease as tp53-mutated aml?
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
8:14
progress in the treatment of tp53 mutated aml
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
9:16
protrombin time (pt) & activated partial tromboplastin time (aptt)|coagulation analyzer|wila djami
-
52:06
understanding monoclonal antibody unfolding and aggregation
-
10:22
neoplasia 4: p53 gene: the guardian of the genome. functions, regulation and inactivation
-
0:42
talquetamab treatment in patients with r/r myeloma with prior exposure to t-cell-directed therapies
-
1:31
ongoing trials in aml and hr-mds: enhance, enhance-2 and enhance-3
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
1:07
testing for ighv and tp53 mutations to guide treatment decisions in cll
-
2:58
long-term follow-up: phase ii study of apr-246 aza in tp53-mutated mds & aml
-
1:23
immunological impact of tp53 in mds
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
3:39
the association between prior exposure to lenalidomide and tp53-mutated aml/mds
-
1:03
significance of p53 mutations in aml
-
0:58
options available to patients with tp53-mutated mds beyond stem cell transplantation
-
2:50
magrolimab in tp53 mutated aml and mds
-
1:59
depth of molecular response in patients with tp53m mds & aml treated with magrolimab and azacitidine